Viking Therapeutics News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

29.11.17	EARS Pinched By HEALOS Data, EGLT Does It Again, JAVELIN Gastric 300 Misses Mark (RTTNews)
28.11.17	Viking Therapeutics Announces Positive Top-Line Results from Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture (PR Newswire)
08.11.17	Viking Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update (PR Newswire)
01.11.17	Viking Therapeutics to Report Financial Results for Third Quarter 2017 on November 8, 2017 (PR Newswire)
24.10.17	Viking Therapeutics Presents Results from In Vivo Study of VK2809 in Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) at the Annual Meeting of the American Association for the Study of Liver... (PR Newswire)
23.10.17	Viking Therapeutics Presents Results from Proof-of-Concept Study of VK0214 in In Vivo Model of X-Linked Adrenoleukodystrophy (X-ALD) at the 87th Annual Meeting of the American Thyroid Association (PR Newswire)
04.10.17	Viking Therapeutics Announces Top-Line Results from Proof-of-Concept Study of VK0214 in In Vivo Model of X-Linked Adrenoleukodystrophy (X-ALD) (PR Newswire)
29.09.17	Viking Therapeutics Announces Purchase Agreements for up to $16.25 Million with Lincoln Park Capital (PR Newswire)
25.09.17	Viking Therapeutics to Host Key Opinion Leader Event to Discuss Musculoskeletal Therapeutics in Hip Fracture and Other Settings (PR Newswire)
11.09.17	Viking Therapeutics Announces Results of Gene Expression Analysis from In Vivo Study of VK2809 in Non-Alcoholic Steatohepatitis (NASH) (PR Newswire)
07.09.17	Viking Therapeutics Announces Presentation of Data from In Vivo Proof-of-Concept Study of VK2809 in Glycogen Storage Disease Ia (GSD Ia) at the 13th International Congress of Inborn Errors of... (PR Newswire)
05.09.17	Viking Therapeutics to Present at Rodman & Renshaw's 19th Annual Global Investment Conference (PR Newswire)
09.08.17	Viking Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update (PR Newswire)
02.08.17	Viking Therapeutics to Report Financial Results for Second Quarter 2017 After Market Close on August 9, 2017 (PR Newswire)
13.07.17	NVS Gets Thumbs Up, Two Biosimilar Candidates To Face FDA Panel, VKTX On Track (RTTNews)
12.07.17	Viking Therapeutics Completes Enrollment in Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture (PR Newswire)
14.06.17	Viking Therapeutics Announces $4.3 Million Registered Direct Offering (PR Newswire)
06.06.17	Viking Therapeutics Announces Promising Top Line Results from In Vivo Study of VK2809 in Non-Alcoholic Steatohepatitis (NASH) (PR Newswire)
03.05.17	Viking Therapeutics to Report Financial Results for First Quarter 2017 After Market Close on May 10, 2017 (PR Newswire)
28.03.17	Viking Therapeutics to Present at H.C. Wainwright & Co.'s 1st Annual NASH Investor Conference (PR Newswire)
22.03.17	FDA Nod For Parkinson's Drug, ABIO Awaits Data In Q3, Busy Year Ahead For VKTX (RTTNews)
21.03.17	Viking Therapeutics Reports Fourth Quarter and Year-End 2016 Financial Results and Provides Corporate Update (PR Newswire)
02.03.17	Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2016 After Market Close on March 21, 2017 (PR Newswire)
28.02.17	Viking Therapeutics to Present at Upcoming Investor Conferences (PR Newswire)
14.02.17	Viking Therapeutics and PoC Capital Enter Agreement to Fund Clinical Development of VK2809 in Glycogen Storage Disease Ia (GSD Ia) (PR Newswire)
09.02.17	Viking Therapeutics Announces Initial Results from In Vivo Proof-of-Concept Study of VK2809 in Glycogen Storage Disease Ia (GSD Ia) (PR Newswire)
07.02.17	Viking Therapeutics to Present at 2017 BIO CEO & Investor Conference (PR Newswire)
10.01.17	Gainers & Losers Of The Day: DFFN, ETRM, GNVC, EGRX, ADHD... (RTTNews)
05.01.17	Viking Therapeutics Announces Senior Level Appointments to Management Team (PR Newswire)
21.12.16	Viking Therapeutics to Present at Biotech Showcase 2017 (PR Newswire)
06.12.16	Viking Therapeutics Receives Orphan Drug Designation for VK0214 from the U.S. Food and Drug Administration for the Treatment of X-Linked Adrenoleukodystrophy (PR Newswire)
29.11.16	Viking Therapeutics to Present at the LD Micro Main Event (PR Newswire)
11.04.16	VKTX Prices Offering At $1.25/Share (RTTNews)
18.11.15	ATNM Marches Ahead, Good News From CDNA, It's Twofer For DEPO, INFI Reaches Mark (RTTNews)
21.10.15	SNTA's GALAXY-2 Dies, NBIX For The Long Haul, VKTX Moving Ahead (RTTNews)
01.09.15	Viking Therapeutics Initiates Clinical Trial For VK5211 - Quick Facts (RTTNews)
05.05.15	Ligand Pharma Partner Viking Therapeutics Closes IPO Of 3 Mln Shares (RTTNews)
29.04.15	Ligand Pharma Partner Viking Therapeutics Prices IPO At $8.00/shr - Quick Facts (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	302.80	1.30 %	K V
Alcon	76.88	0.65 %	K V
Sika	218.00	0.37 %	K V
Kuehne+Nagel Int	202.60	-0.20 %	K V
Logitech Intl	78.28	-0.33 %	K V
ABB	49.25	-1.44 %	K V
Holcim	87.68	-1.55 %	K V
Zurich Insur Gr	531.20	-1.63 %	K V
Roche Hldg G	267.20	-1.69 %	K V
UBS Group	29.78	-1.94 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Viking Therapeutics Inc

Aktien Top/Flop

Meistgelesene Nachrichten